AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31715434
Drug: Third‐generation drug‐eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third‐generation drug‐eluting stents for primary PCI
Trial: 19893109
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (Ringer solution 1 ml/kg/h)
Trial: 17028485
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers
Trial: 17028485
Drug: Insulin-sensitizing and
RxNorm normalized name: insulin degludec and liraglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-sensitizing and antihyperglycemic agents
Trial: 9427987
Drug: One injection
RxNorm normalized name: naloxone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection of a mixture of balanced salt solution, 2% lidocaine, 0.5% bupivacaine, and hyaluronidase
Trial: 9427987
Drug: Two injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two injections of a mixture of balanced salt solution, 2% lidocaine, 0.5% bupivacaine, and hyaluronidase
Trial: 8424029
Drug: Discontinue breast-feeding,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinue breast-feeding, substitute formula and administer phototherapy
Trial: 8424029
Drug: Continue breast-feeding,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue breast-feeding, administer phototherapy
Trial: 3308702
Drug: Cream (saturated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream (saturated fat)
Trial: 27204
Drug: Promethazine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine (10 mg)
Trial: 6398313
Drug: Thymopentin 50
RxNorm normalized name: Thymopentine
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin 50 mg via prolonged i.v. injection, 3 times weekly for 3 to 20 weeks.
Trial: 6398313
Drug: Different s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different s.c. doses of thymopentin in a crossover fashion for more than two years.
Trial: 6398313
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment and medication-free intervals.
Trial: 29768139
Drug: Canakinumab 150
RxNorm normalized name: canakinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab 150 mg subcutaneously every 4 weeks
Trial: 29768139
Drug: Canakinumab 300
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab 300 mg every 4 weeks
Trial: 12730702
Drug: Adequate intake
RxNorm normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate intake of folate, B12, and B6 in doses comparable to or above FDA recommendations
Trial: 11201834
Drug: Standard combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard combined therapy with nonsteroid antiinflammatory drugs, reducers of trophic processes, physiotherapy
Trial: 11201834
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus bioresonance treatment (BRT)
Trial: 6342965
Drug: Osmosin (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osmosin (7 mg indomethacin per hour over a period of approximately 10 hours)
Trial: 6342965
Drug: Piroxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (20 mg per day for 4 weeks)
Trial: 12296776
Drug: Nd:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAG laser treatment
Trial: 28389075
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (1% unbuffered sodium hypochlorite and 15% EDTA solution)
Trial: 17726570
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus rosiglitazone
Trial: 18693456
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus metformin
Trial: 17726570
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus acarbose
Trial: 25514302
Drug: Entecavir (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir (0.5 mg daily)
Trial: 22543151
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (hepatoprotective drugs only)
Trial: 18461096
Drug: Glucose (1
RxNorm normalized name: Fludeoxyglucose (18F)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose (1 g x kg body mass(‐1))
Trial: 26432775
Drug: Sensor-augmented pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor-augmented pump therapy (SAP) only
Trial: 24490236
Drug: Cue-centered treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cue-centered treatment
Trial: 30371301
Drug: Exenatide once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide once-weekly
Trial: 21434995
Drug: Sitagliptin to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin to exenatide once-weekly
Trial: 21434995
Drug: Pioglitazone to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone to exenatide once-weekly
Trial: 12741429
Drug: Estradiol 2
RxNorm normalized name: estradiol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol 2 mg
Trial: 18821092
Drug: Estradiol 2
RxNorm normalized name: estradiol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol 2 mg + NETA 1 mg
Trial: 27623621
Drug: Nimodipine alone
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine alone (30 mg/time, 3 times daily)
Trial: 16285195
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug treatment
Trial: 22633824
Drug: REGN727 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGN727 150 mg every 2 weeks
Trial: 3548345
Drug: Rapid regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid regimen (a mixture of regular and Lente insulins twice daily)
Trial: 3548345
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (Lente insulin once daily)
Trial: 3548345
Drug: Rapid/intravenous regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid/intravenous regimen (the 'rapid' regimen preceded by overnight intravenous infusion of regular insulin)
Trial: 30683146
Drug: Vehicle ointment
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle ointment (control)
Trial: 18422390
Drug: Niacin extended
RxNorm normalized name: Niacin Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin extended release and simvastatin (NER/S) 2,000/40 mg/day
Trial: 14578234
Drug: Serum triglyceride,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum triglyceride, HDL cholesterol, and insulin resistance values in 2000
Trial: 29855986
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract EGb 761, 120 mg twice a day
Trial: 7794701
Drug: Nizatidine 150
RxNorm normalized name: nizatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 150 mg twice daily
Trial: 16398426
Drug: Traditional herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional herbal medicine (CM) therapy
Trial: 18184543
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (WM) therapy
Trial: 9690725
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg o.m. for 4-8 weeks
Trial: 9690725
Drug: Sucralfate 2
RxNorm normalized name: sucralfate 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 2 g b.d. for 4-8 weeks
Trial: 581421
Drug: Oral antibacterial
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibacterial preparation with phthalylsulfathiazole and neomycin
Trial: 581421
Drug: Oral antibacterial
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibacterial preparation with phthalylsulfathiazole, neomycin, and tetracycline
Trial: 581421
Drug: No antibacterial
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibacterial preparation
Trial: 20572888
Drug: Petrolatum containing
RxNorm normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Petrolatum containing cream (GEHWOL med Schrundensalbe)
Trial: 20572888
Drug: Urea 10%
RxNorm normalized name: UREA 10% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea 10% cream (GEHWOL med Lipidro‐Crème)
Trial: 8503942
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 and vitamin B6 (pyridoxine) administered together
Trial: 8503942
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 administered alone
Trial: 29178564
Drug: UC-MSC infusion
RxNorm normalized name: Astri-UC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC-MSC infusion (1 × 10^6 /kg body weight)
Trial: 29178564
Drug: UC-MSC infusion
RxNorm normalized name: Astri-UC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC-MSC infusion
Trial: 19841335
Drug: 3-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day course of amoxicillin
Trial: 11345650
Drug: Amsalog 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amsalog 180 mg/m2 per day for 5 days
Trial: 11345650
Drug: Amsalog administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amsalog administered via peripheral venous line
Trial: 9574945
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (in female subjects)
Trial: 20129336
Drug: Third-generation thermal
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-generation thermal uterine balloon therapy system with postprocedure curettage
Trial: 20129336
Drug: Third-generation thermal
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-generation thermal uterine balloon therapy system without postprocedure curettage
Trial: 16619231
Drug: Medium dose:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose: 2.2 x 10(11) platelets/m(2)
Trial: 16619231
Drug: Higher dose:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose: 4.4 x 10(11) platelets/m(2)
Trial: 8006274
Drug: Active nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active nitroglycerin patch therapy (0.4 mg/h, 12 h on/off)
Trial: 18793563
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg)
Trial: 11553256
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at 0.1 microg kg(‐1) min(‐1)
Trial: 14665895
Drug: Finasteride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5 mg once daily)
Trial: 9732187
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release (SR) alfuzosin (5 mg twice daily)
Trial: 9732187
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SR alfuzosin and finasteride (5 mg once daily)
Trial: 2191978
Drug: Furosemide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (20 mg) with captopril
Trial: 2191978
Drug: Furosemide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (20 mg) alone
Trial: 1093503
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide for six months
Trial: 1093503
Drug: Low-dose cyclophosphamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclophosphamide plus prednisone for six months
Trial: 25464934
Drug: Combination Treatment
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Treatment (for non-remitted patients)
Trial: 25751116
Drug: Both Treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Treatments
Trial: 16642612
Drug: Acupoint catgut
RxNorm normalized name: CATGUT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint catgut embedding therapy at Dachangshu (BL 25), Zusanli (ST 36), Shangjuxu (ST 37)
Trial: 16642612
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of salicylazosulfapyridine, 4-6 g/day
Trial: 7537286
Drug: Risperidone 6
RxNorm normalized name: risperidone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 6 mg/day
Trial: 10073740
Drug: GI198745 (dutasteride)
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GI198745 (dutasteride) above 1 mg daily doses
Trial: 7589382
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg rhDNase twice daily for 14 days
Trial: 7589382
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg rhDNase twice daily during the OEP
Trial: 16982546
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) with a central dose of 15 Gy x 3 within 5-8 days
Trial: 3533421
Drug: Luteinizing hormone
RxNorm normalized name: LUTEINIZING HORMONE
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone releasing hormone (LHRH) injection
Trial: 3533421
Drug: Testosterone injection
RxNorm normalized name: testosterone Injection
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone injection
Trial: 25896747
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) once a week for 12 weeks
Trial: 16766543
Drug: Candesartan 4-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 4-8 mg/day
Trial: 6339152
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion with glucose
Trial: 25738669
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of valganciclovir therapy
Trial: 15562053
Drug: IV tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV tranexamic acid (TA) 15 mg/kg bolus over 30 min followed by IV infusion of 10 mg . kg(‐1) . h(‐1) for 12 h
Trial: 15562053
Drug: IV tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV tranexamic acid (TA) similar to TA-long but infusion discontinued 2 h after deflation, followed by oral TA 1 g after 6 and 12 h
Trial: 11054523
Drug: Deferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred treatment policy (DAD)
Trial: 1283143
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy with additional external beam radiotherapy (40 Gy in 10-20 fractions)
Trial: 1283143
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Laser therapy + external beam radiotherapy)
Trial: 21503180
Drug: Caffeine 5
RxNorm normalized name: caffeine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 5 mg/kg
Trial: 6728874
Drug: Ethanol 0.5
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.5 g/kg and Caffeine 5 mg/kg combined
Trial: 23292040
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once daily with itopride 50 mg three times daily
Trial: 1984215
Drug: Intracervical prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical prostaglandin (PG) E2 gel
Trial: 1984215
Drug: Double balloon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double balloon device with PGE2 gel
Trial: 1984215
Drug: Double balloon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double balloon device with placebo gel
Trial: 6337609
Drug: mianserin 60
RxNorm normalized name: mianserin 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mianserin 60 mg nocte
Trial: 6337609
Drug: nomifensine 150
RxNorm normalized name: nomifensine
DrugBank: Nomifensine (DB04821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nomifensine 150 mg daily
Trial: 27142674
Drug: Intensity Modulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity Modulation Radiation Therapy (IMRT)
Trial: 25372582
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg/day and 40 mg/day combined
Trial: 20473044
Drug: Venlafaxine 37.5
RxNorm normalized name: venlafaxine 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 37.5 mg/d
Trial: 16480165
Drug: Reduced, escalating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced, escalating dose (one to three needle) protocol
Trial: 16480165
Drug: Acupuncture with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture with spirituality-focused group therapy
Trial: 16480165
Drug: Acupuncture without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acupuncture without spirituality-focused group therapy
Trial: 3202925
Drug: Alcohol ingestion
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol ingestion (mean serum ethanol 35 mmol/l)
Trial: 3202925
Drug: Alcohol ingestion
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol ingestion (serum ethanol 21 mmol/l)
Trial: 27993588
Drug: Verum-focused extracorporeal
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verum-focused extracorporeal shock wave therapy (energy flux density, .06‐.09mJ/mm2; pulse ratio per point, 200)
Trial: 31774125
Drug: Parathyroid hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parathyroid hormone (PTH)
Trial: 15577058
Drug: PTH and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH and anti-resorptive agents (concurrent or sequential therapies)
Trial: 3279757
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g amoxycillin suspension twice a day for 8 days
Trial: 16450662
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg ZOL every two weeks
Trial: 16450662
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg ZOL every four weeks
Trial: 2333541
Drug: Premedicated with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedicated with intramuscular atropine 0.015 mg/kg
Trial: 12224691
Drug: Systemic corticosteroids
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic corticosteroids with orally administered prednisone (group A)
Trial: 8907140
Drug: morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: morphine sulfate solution or controlled‐release morphine tablets
Trial: 8907140
Drug: morphine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine administration
Trial: 6849724
Drug: Chlormethiazole (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormethiazole (mean 6.0 mg kg‐1)
Trial: 6849724
Drug: Thiopentone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (mean 4.5 mg kg‐1)
Trial: 27569824
Drug: L-carnitine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (6 g/L)
Trial: 31393619
Drug: L-carnitine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (12 g/L)